Brand Name | Status | Last Update |
---|---|---|
gleevec | New Drug Application | 2024-07-22 |
imatinib | ANDA | 2024-04-20 |
imatinib mesylate | ANDA | 2025-01-19 |
imkeldi | New Drug Application | 2024-12-05 |
Indication | MeSH | Ontology | ICD-10 | Ph 1 | Ph 2 | Ph 3 | Ph 4 | Other | Total |
---|---|---|---|---|---|---|---|---|---|
Leukemia | D007938 | — | C95 | 1 | — | — | — | — | 1 |
Bcr-abl positive chronic myelogenous leukemia | D015464 | EFO_0000340 | — | 1 | — | — | — | — | 1 |
Myeloid leukemia | D007951 | — | C92 | 1 | — | — | — | — | 1 |
Drug common name | Imatinib mesylate |
INN | imatinib |
Description | Imatinib is a benzamide obtained by formal condensation of the carboxy group of 4-[(4-methylpiperazin-1-yl)methyl]benzoic acid with the primary aromatic amino group of 4-methyl-N(3)-[4-(pyridin-3-yl)pyrimidin-2-yl]benzene-1,3-diamine. Used (as its mesylate salt) for treatment of chronic myelogenous leukemia and gastrointestinal stromal tumours. It has a role as an apoptosis inducer, a tyrosine kinase inhibitor and an antineoplastic agent. It is a N-methylpiperazine, a member of pyridines, a member of benzamides, an aromatic amine and a member of pyrimidines. It is functionally related to a benzamide. |
Classification | Small molecule |
Drug class | tyrosine kinase inhibitors |
Image (chem structure or protein) | ![]() |
Structure (InChI/SMILES or Protein Sequence) | CS(=O)(=O)O.Cc1ccc(NC(=O)c2ccc(CN3CCN(C)CC3)cc2)cc1Nc1nccc(-c2cccnc2)n1 |
PDB | — |
CAS-ID | 220127-57-1 |
RxCUI | — |
ChEMBL ID | CHEMBL1642 |
ChEBI ID | 31690 |
PubChem CID | 5291 |
DrugBank | DB00619 |
UNII ID | BKJ8M8G5HI (ChemIDplus, GSRS) |